Norway· NO-ID_4DAB1027-D7F8-48D2-A230-171404C4B67F
Enhertu
A trastuzumab deruxtecan product containing trastuzumab deruxtecan, registered in Norway by Daiichi Sankyo Europe GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Trastuzumab deruxtecan is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FD04 (trastuzumab deruxtecan), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Trastuzumab deruxtecan · ATC L01FD04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trastuzumab deruxtecan costs, country by country.
Normalised to the WHO defined daily dose (18 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trastuzumab deruxtecan · price per daily dose (18 mg)
USD · FX 28 Sept 2026
- CH Switzerland$337.42
The record
At a glance
FEST (Norway)- Active substance
- Trastuzumab Deruxtecan
- Manufacturer
- Daiichi Sankyo Europe GmbH
- Country
- Norway (NO)
- ATC code
- L01FD04
- ATC class
- Trastuzumab deruxtecan
- Defined daily dose
- 18 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_4DAB1027-D7F8-48D2-A230-171404C4B67F
- no_varenummer153855100NOK 21789.7
- gtin4260161041250
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
61 interactions on record for trastuzumab deruxtecan.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trastuzumab deruxtecan · interactions on record
61 records
- 28 severe
- 33 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trastuzumab deruxtecan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainENHERTU 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONDaiichi Sankyo Europe Gmbh
- FinlandEnhertuAbacus Medicine A/S
- United KingdomEnhertu 100mg powder for concentrate for solution for infusion vialsDaiichi Sankyo UK Ltd
- IrelandEnhertu 100 mg powder for concentrate for solution for infusionDaiichi Sankyo Europe GmbH
- IcelandEnhertuDAIICHI SANKYO EUROPE GmbH*
- PolandEnhertuDaiichi Sankyo Europe GmbH
- BelgiumEnhertu 100 mgDaiichi Sankyo Europe
- SwedenEnhertu 100 mg Pulver till koncentrat till infusionsvätska, lösningDaiichi Sankyo Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Enhertu
- Liechtenstein · Enhertu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/17bf9f9a-41c6-4d5b-b7d0-cd8f200632af GET /v1/drugs/17bf9f9a-41c6-4d5b-b7d0-cd8f200632af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Trastuzumabderukstekan",
"merkevare_id": "ID_4DAB1027-D7F8-48D2-A230-171404C4B67F",
"name_form_strength": "Enhertu pulv til kons til inf væske, oppl 100 mg",
"prescription_group": "C"
}See everything about trastuzumab deruxtecan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.